Hanmei Xu

3.2k total citations · 1 hit paper
53 papers, 2.4k citations indexed

About

Hanmei Xu is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Hanmei Xu has authored 53 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 23 papers in Oncology and 11 papers in Immunology. Recurrent topics in Hanmei Xu's work include Cell Adhesion Molecules Research (10 papers), Antimicrobial Peptides and Activities (7 papers) and CAR-T cell therapy research (7 papers). Hanmei Xu is often cited by papers focused on Cell Adhesion Molecules Research (10 papers), Antimicrobial Peptides and Activities (7 papers) and CAR-T cell therapy research (7 papers). Hanmei Xu collaborates with scholars based in China, Czechia and United States. Hanmei Xu's co-authors include Sarra Setrerrahmane, Erhao Zhang, Weiyan Qi, Heng Zheng, Xingzhen Lao, Fatuma Felix Felician, Chunlei Xia, Jian Sun, Xinyue Kang and Fanyi Dong and has published in prestigious journals such as Journal of the American Chemical Society, Nucleic Acids Research and Scientific Reports.

In The Last Decade

Hanmei Xu

52 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

DRAMP 3.0: an enhanced comprehensive data repository of antimicrobial peptides

2021 199 citations Hanmei Xu, Heng Zheng et al. profile →

Peers

Countries citing papers authored by Hanmei Xu

Since Specialization

Citations

This map shows the geographic impact of Hanmei Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hanmei Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hanmei Xu more than expected).

Fields of papers citing papers by Hanmei Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hanmei Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hanmei Xu. The network helps show where Hanmei Xu may publish in the future.

Co-authorship network of co-authors of Hanmei Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Hanmei Xu. A scholar is included among the top collaborators of Hanmei Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hanmei Xu. Hanmei Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	‘Renovation of old drugs’ – can peptide drug conjugates lead the post-ADC era? 2023 ·Australian Journal of Chemistry ·(unknown), Peng R. Chen, Hui Zhang, Sarra Setrerrahmane, Hanmei Xu	3
2	Phytochemical Constituents and In-Vitro Anticancer Activity of some Medicinal Plant Extracts against MCF-7 and MDA-MB-435 Human Breast Cancer Cell L 2023 ·Tropical Journal of Natural Product Research ·(unknown), Lu Tang, (unknown), (unknown), (unknown), Hanmei Xu	2
3	CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer 2023 ·Cancer Immunology Immunotherapy ·Peiwei Yang, Yu Fan, (unknown), Ding Xu, Hanmei Xu, Juan Zhang	10
4	Micropeptide MIAC inhibits the tumor progression by interacting with AQP2 and inhibiting EREG/EGFR signaling in renal cell carcinoma 2022 ·Molecular Cancer ·Mengwei Li, Guang‐Xiang Liu, (unknown), Hongqian Guo, Sarra Setrerrahmane, (unknown), Tiantian Li, (unknown), Hanmei Xu	48
5	Integrins as attractive targets for cancer therapeutics 2021 ·Acta Pharmaceutica Sinica B ·Meng Li, Ying Wang, Mengwei Li, (unknown), Sarra Setrerrahmane, Hanmei Xu	135
6	Significantly increased anti‐tumor activity of carcinoembryonic antigen‐specific chimeric antigen receptor T cells in combination with recombinant human IL‐12 2019 ·Cancer Medicine ·(unknown), Peiwei Yang, Erhao Zhang, (unknown), Hui Xu, Mengwei Li, (unknown), Xin Li, Yinan Zhang, Hanmei Xu, (unknown)	56
7	<p>Combined administration of PTX and S-HM-3 in TPGS/Solutol micelle system for oncotarget therapy</p> 2019 ·International Journal of Nanomedicine ·Weiguang Li, Jianpeng Xue, Hanmei Xu	13
8	Anti-Tumor Activity and Pharmacokinetics of AP25-Fc Fusion Protein 2019 ·International Journal of Medical Sciences ·(unknown), (unknown), (unknown), Pengcheng Yu, Hanmei Xu, Junzhi Wang	3
9	Optimized functional and structural design of dual-target LMRAP, a bifunctional fusion protein with a 25-amino-acid antitumor peptide and GnRH Fc fragment 2019 ·Acta Pharmaceutica Sinica B ·Meng Li, Hanmei Xu, Junzhi Wang	9
10	Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy 2018 ·Journal of Hematology & Oncology ·Erhao Zhang, Peiwei Yang, (unknown), Heming Wu, (unknown), Chen Liu, Ying Wang, Jianpeng Xue, Weiyan Qi, (unknown), Shengnan Zhang, (unknown), Hanmei Xu	83
11	Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors 2018 ·Molecular Cancer ·Erhao Zhang, (unknown), Hanmei Xu	83
12	Novel production method of innovative antiangiogenic and antitumor small peptides in <em>Escherichia coli</em> 2017 ·Drug Design Development and Therapy ·Sarra Setrerrahmane, (unknown), (unknown), Heng Zheng, Hanmei Xu	9
13	Enhanced therapeutic effect of an antiangiogenesis peptide on lung cancer in vivo combined with salmonella VNP20009 carrying a Sox2 shRNA construct 2016 ·Journal of Experimental & Clinical Cancer Research ·Changhong Zhao, (unknown), Haoran Cheng, (unknown), Hanmei Xu	41
14	An integrin αvβ3 antagonistic modified peptide inhibits tumor growth through inhibition of the ERK and AKT signaling pathways 2016 ·Oncology Reports ·Lirong Hu, Jingjing Wang, Ying Wang, Hanmei Xu	10
15	Anti-tumor peptide AP25 decreases cyclin D1 expression and inhibits MGC-803 proliferation via phospho-extracellular signal-regulated kinase-, Src-, c-Jun N-terminal kinase-and phosphoinositide 3-kinase-associated pathways 2015 ·Molecular Medicine Reports ·(unknown), Tao Cheng, Lijun Zhang, Beicheng Sun, Lei Deng, Hanmei Xu	8
16	Generation of hepatitis B virus PreS2-S antigen in Hansenula polymorpha 2014 ·Virologica Sinica ·Xiaowei Xu, (unknown), Xiaoxiao Chen, Junwei Ge, Zhenxing Xu, Hongying Huang, (unknown), Yue Gu, (unknown), Jianqiang Li, Hanmei Xu	9
17	PEGylated HM-3 presents anti-rheumatic bioactivity by inhibiting angiogenesis and inflammation 2013 ·Journal of Materials Chemistry B ·Hong Shen, (unknown), Jialiang Hu, Xiaojuan Zhang, Jingjing Wang, Wenjing Wang, (unknown), Hanmei Xu	11
18	Subacute toxicity of antimicrobial peptide S-thanatin in ICR mice 2012 ·Peptides ·Guoqiu Wu, Xuepeng Deng, (unknown), Zilong Shen, Hanmei Xu	11
19	Application of immobilized thrombin for production of S-thanatin expressed in Escherichia coli 2011 ·Applied Microbiology and Biotechnology ·Guoqiu Wu, Xuepeng Deng, Xiaofang Li, Xiyong Wang, Shenglan Wang, Hanmei Xu	6
20	Research of McAb-Based Competitive ELISA for Detecting HM-3 Residues in Serum 2010 ·Pharmaceutical biotechnology ·Hanmei Xu	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact